Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Telisotuzumab Adizutecan in MET-Amplified Solid Tumors
jRCT2031250443Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of telisotuzumab adizutecan in Nonhematologic neoplasms, sponsored by AbbVie Inc. Started Nov 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250443.